In last trading session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) saw 13.24 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $5.75 trading at $0.17 or 3.05% at ring of the bell on the day assigns it a market valuation of $2.31B. That closing price of RXRX’s stock is at a discount of -114.96% from its 52-week high price of $12.36 and is indicating a premium of 34.09% from its 52-week low price of $3.79. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 26.06 million shares which gives us an average trading volume of 25.46 million if we extend that period to 3-months.
For Recursion Pharmaceuticals Inc (RXRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.43. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Upright in the green during last session for gaining 3.05%, in the last five days RXRX remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $5.75 price level, adding 5.89% to its value on the day. Recursion Pharmaceuticals Inc’s shares saw a change of -14.94% in year-to-date performance and have moved 8.08% in past 5-day. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) showed a performance of -11.94% in past 30-days. Number of shares sold short was 88.5 million shares which calculate 4.7 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 4.17% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -4.35% in reaching the projected high whereas dropping to the targeted low would mean a loss of -4.35% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -35.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 5.03% while estimates for its earnings growth in next 5 years are of 20.68%.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Insiders are in possession of 3.57% of company’s total shares while institution are holding 77.31 percent of that, with stock having share float percentage of 80.17%. Investors also watch the number of corporate investors in a company very closely, which is 77.31% institutions for Recursion Pharmaceuticals Inc that are currently holding shares of the company. ARK INVESTMENT MANAGEMENT LLC is the top institutional holder at RXRX for having 28.14 million shares of worth $211.07 million. And as of 2024-06-30, it was holding 11.6199 of the company’s outstanding shares.
The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 26.59 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.9787 of outstanding shares, having a total worth of $199.42 million.
On the other hand, ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 19.28 shares of worth $110.88 million or 4.88% of the total outstanding shares. The later fund manager was in possession of 12.61 shares on Mar 31, 2025 , making its stake of worth around $72.49 million in the company or a holder of 3.19% of company’s stock.
